Last reviewed · How we verify
Treatment 1. Metoclopramide
Metoclopramide, marketed by Hamad Medical Corporation, is a well-established treatment in the gastrointestinal market. The drug's key composition patent is set to expire in 2028, providing a period of exclusivity that supports its market position. However, the lack of a clear primary indication and revenue data poses a significant risk in assessing its competitive landscape and financial performance.
At a glance
| Generic name | Treatment 1. Metoclopramide |
|---|---|
| Also known as | primpran |
| Sponsor | Hamad Medical Corporation |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- A Study Evaluating the Safety, Tolerability and Pharmacokinetics of ASY202 in Healthy Adults (PHASE1)
- NEPC Study: An Exploratory Safety and Efficacy Study With PSMA, SSTR2 and GRPR Targeted Radioligand Therapy in Metastatic Neuroendocrine Prostate Cancer. (PHASE1)
- Gastric Volumes by US in Term Parturients Undergoing CS With and Without Metoclopramide (PHASE4)
- Non-opioid Anesthesia Based on Thoracic Paravertebral Block During Laparoscopic Sleeve Gastrectomy (NA)
- Efficacy and Safety of Ondansetron Versus Metaclopromide Treatment in Infants With Gastro Oesophageal Reflux (NA)
- A Pilot Clinical Trial of a New Neuromodulation Device for Acute Attacks of Migraine in Children and Adolescents (PHASE3)
- Home Detox in Medication Overuse Headache (MOH) During Covid-19 Emergency (PHASE4)
- Comparison of Efficacy of Metoclopramide , Promethazine and Prochloroperazine in the Treatment of Vertigo. (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Treatment 1. Metoclopramide CI brief — competitive landscape report
- Treatment 1. Metoclopramide updates RSS · CI watch RSS
- Hamad Medical Corporation portfolio CI